Literature DB >> 12849297

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment.

Charles DeCarli1.   

Abstract

Mild cognitive impairment (MCI) is a recently described syndrome that is currently thought of as a transition phase between healthy cognitive ageing and dementia. Although this notion seems to be reasonable, the general nature of the term MCI--including its many definitions--makes accurate accounting of the prevalence, prognosis, and potential benefit from treatment somewhat difficult. The differences in cognitive profile and clinical progression among individuals with MCI are generally recognised. However, recent evidence also suggests that the aetiological heterogeneity among individuals with MCI could be greater than previously reported. For example, cerebrovascular disease seems to be underestimated as a potential cause of MCI. In this review, I attempt to recognise workable definitions of MCI to discuss the prevalence, pathophysiology, prognosis, and possibilities for treatment of this disorder.

Entities:  

Mesh:

Year:  2003        PMID: 12849297     DOI: 10.1016/s1474-4422(03)00262-x

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  158 in total

1.  Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments.

Authors:  Carrie B Peltz; María M Corrada; Daniel J Berlau; Claudia H Kawas
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

2.  Sex differences in the association of Framingham Cardiac Risk Score with cognitive decline in community-dwelling elders without clinical heart disease.

Authors:  Gail A Laughlin; Linda K McEvoy; Denise von Mühlen; Lori B Daniels; Donna Kritz-Silverstein; Jaclyn Bergstrom; Kevin Cummins; Claudia Der-Martirosian; Simerjot K Jassal; Elizabeth Barrett-Connor
Journal:  Psychosom Med       Date:  2011-09-23       Impact factor: 4.312

3.  Performance-based measures of everyday function in mild cognitive impairment.

Authors:  Terry E Goldberg; Jeremy Koppel; Lynda Keehlisen; Erica Christen; Ute Dreses-Werringloer; Concepcion Conejero-Goldberg; Marc L Gordon; Peter Davies
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

4.  Biomarkers in Alzheimer's disease drug development.

Authors:  Kaj Blennow
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

5.  Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease.

Authors:  Qiying Sun; Harald Hampel; Kaj Blennow; Simone Lista; Allan Levey; Beisha Tang; Rena Li; Yong Shen
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study.

Authors:  Andrea L C Schneider; Andreea M Rawlings; A Richey Sharrett; Alvaro Alonso; Thomas H Mosley; Ron C Hoogeveen; Christie M Ballantyne; Rebecca F Gottesman; Elizabeth Selvin
Journal:  Eur Heart J       Date:  2014-03-30       Impact factor: 29.983

Review 7.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

8.  Demographic and CT scan features related to cognitive impairment in the first year after stroke.

Authors:  S M C Rasquin; F R J Verhey; R J van Oostenbrugge; R Lousberg; J Lodder
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-11       Impact factor: 10.154

Review 9.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

Review 10.  Mild cognitive impairment: ten years later.

Authors:  Ronald C Petersen; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Yonas E Geda; Robert J Ivnik; Glenn E Smith; Clifford R Jack
Journal:  Arch Neurol       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.